# Glenn Rockman

> Glenn Rockman is a Series B investor at Adjuvant Capital backing Biotechnology. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital)
- Location: New York, United States
- Total investments: 9
- Last investment: Oct 2025
- Lead investor: 78%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/grockman

Glenn Rockman is a Series B investor at Adjuvant Capital in New York focused on Biotechnology and Health Care. Glenn Rockman is the Founder and Managing Partner at Adjuvant Capital.

## Contacts

5 contacts available for Glenn Rockman: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/glenn-rockman?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 44% |
| Health Care | 3 | 33% |
| Medical | 2 | 22% |
| Medical Device | 2 | 22% |
| Genetics | 1 | 11% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series A | 2 | 22% |
| Series C | 1 | 11% |
| Series D | 1 | 11% |
| Funding Round | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 44% |
| Austria | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VitriVax | VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. | $17.3M | Series B | Oct 22, 2025 |  |
| Codagenix | Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $25M | Series B | Feb 15, 2023 |  |
| InDevR | InDevR is a biotechnology company that develops and manufactures microarray technologies and applications as well as novel solutions to support the life sciences industry. It was incorporated in 2003 and is based in Boulder, Colorado. | $9M | Series B | Jan 17, 2023 |  |
| VitriVax | VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, moreaffordable, and more accessible globally.VitriVax is headquartered in Boulder, Colorado. |  | Series A | Jul 07, 2021 |  |
| Codagenix | Codagenix is a developer of live-attenuated viral vaccines intended to provide target antigens placed in an attenuated backbone virus.The company's vaccines use Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain, enabling researchersto invent viral vaccine to treat influenza, dengue, polio, and other diseases. Codagenix has been developing a COVID-19 vaccine as well. | $20M | Series B | Jan 13, 2020 |  |
| Themis Bioscience | Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies. | $43.9M | Series D | Sep 18, 2019 |  |
| Themis Bioscience | Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing andacquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies. | $11M | Series C | Jan 03, 2018 |  |
| PATH | PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partnersempower people to achieve their full potential. | $25M |  | Feb 01, 2017 |  |
| InDevR | InDevR is a biotechnology company that develops and manufactures microarray technologies and applications as well as novel solutions to support the life sciences industry. It was incorporated in 2003 and is based in Boulder, Colorado. | $7M | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund, 2 deals together
- [Euclidean Capital](https://shizune.co/investors/profile/euclidean-capital) — VC Fund, 2 deals together
- [Omnes Capital](https://shizune.co/investors/profile/omnes-capital) — VC Fund, 2 deals together
- [Ventech](https://shizune.co/investors/profile/ventech-capital) — VC Fund, 2 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 1 deal together
- [bioMerieux](https://shizune.co/investors/profile/biomerieux) — VC Fund, 1 deal together

## About Adjuvant Capital

VC Fund · New York, United States

Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.

5 contacts available at Adjuvant Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Glenn Rockman | Founder and Managing Partner | — |
| Michael Chang | Principal | — |
| Charlie Petty | Principal | — |
| Jenny Yip | Managing Partner | — |
| Kabeer Aziz | Principal | https://shizune.co/investors/profile/kabeer-aziz |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Glenn Rockman invest in?

Glenn Rockman invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Glenn Rockman?

Public channels for Glenn Rockman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Glenn Rockman last invest?

The most recent investment recorded for Glenn Rockman closed in Oct 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co